drug
SOLIQUA 100/33
updated 5mo agoby Sanofi-Aventis US LLC
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval48 co-mentions · 12 sources
- druginsulin glargine LA24 co-mentions · 12 sources
- company$SNYSanofi24 co-mentions · 12 sources
- company$SNYNFSanofi24 co-mentions · 12 sources
- companySanofi-Aventis US LLC24 co-mentions · 12 sources
- drugToujeo LA24 co-mentions · 12 sources
- drug(insulin glargine + lixisenatide)24 co-mentions · 12 sources
- drugAbasaglar24 co-mentions · 12 sources
all catalysts(0)
nothing on the calendar yet
Trials studying SOLIQUA 100/33
- phase4A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
- phase3AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
- phase4A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
- phase3A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
- phase3A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
- phase3A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
- phase3A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
- phase3A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
News(5)
- Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalryThe weekly insulin Onswik will now be available to U.S. patients after initial approvals in Europe, Mexico and Japan.biospace · 9d ago
- STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and moreSeven months after the launch of its own low-cost insulin brand, California has distributed more than 120,000 five-pen packs of insulin glargine priced at $55 eachstat · 1mo ago
- STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and moreIn a win for peptide proponents, an FDA advisory panel recommended compounding pharmacies be allowed to make four of the drugsstat · 2mo ago
- A new, separate outbreak of the diarrhea-causing parasiteA win for peptide proponents, autism advisory committees clash, and more health news from Morning Roundsstat · 2mo ago
- STAT+: Popular insulin product enters shortage as other pens leave marketThe Lantus Solostar insulin pen isn't in official FDA shortage, but patients are having a tough time finding it.stat · 2mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that